The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
Open accessAbstract
This article reviews ocular adverse events (AEs) reported in association with administration of antibody-drug conjugates (ADCs) in human clinical trials. References reporting ocular toxicity or AEs associated with ADCs were collected using online publication searches. Articles, abstracts, or citations were included if they cited ocular toxicities or vision-impairing AEs with a confirmed or suspected association with ADC administration. Twenty-two references were found citing ocular or vision-impairing AEs in association with ADC administration. All references reported use of ADCs in human clinical trials for treatment of various malignancies. The molecular target and cytotoxic agent varied depending on the ADC used. Ocular AEs affected a diversity of ocular tissues. The most commonly reported AEs involved the ocular surface and included blurred vision, dry eye, and corneal abnormalities (including microcystic corneal disease). Most ocular AEs were not severe (≤ grade 2) or dose limiting. Clinical outcomes were not consistently reported, but when specified, most AEs improved or resolved with cessation of treatment or with ameliorative therapy. A diverse range of ocular AEs are reported in association with administration of ADCs for the treatment of cancer. The toxicologic mechanism(s) and pathogenesis of such events are not well understood, but most are mild in severity and reversible. Drug development and medical professionals should be aware of the clinical features of these events to facilitate early recognition and intervention in the assessment of preclinical development programs and in human clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 669
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Mitri, Z., Constantine, T., & O'Regan, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 519
Strop, P., Liu, S.-H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T.-T., Ho, W.-H., Farias, S., Casas, M. G., Abdiche, Y., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.01.010 · Cited by 505
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
High-dose cytosine arabinoside therapy for refractory leukemia
Herzig, R., Wolff, S., Lazarus, H., Phillips, G., Karanes, C., & Herzig, G. (1983) · Blood · doi:10.1182/blood.v62.2.361.361 · Cited by 372
Contributions of Human Tumor Xenografts to Anticancer Drug Development
Sausville, E. A., & Burger, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3627 · Cited by 348
CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy
Scheuermann, R. H., & Racila, E. (1995) · Leukemia & Lymphoma · doi:10.3109/10428199509059636 · Cited by 323
O’Connell, F. P., Pinkus, J. L., & Pinkus, G. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/617dwb5gnfwxhw4l · Cited by 263
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib, R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1212 · Cited by 260
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., & Bernstein, I. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0100206 · Cited by 230
Larson, R., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E., Sievers, E., Mineur, P., Bennett, J., Berger, M., Eten, C., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221
Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.137 · Cited by 206 · cited 2×
“IMGN242 (huC242-DM4) IMGN242 (huC242-DM4) is a conjugate of a humanized antibody (huC242) and DM4 (a maytansinoid). huC242 demonstrates affinity for a tumor-associated epitope of CanAg, a glycoform molecule of MUC1.”
BackgroundMonoclonal Antibodies in Cancer Therapy: 25 Years of Progress
Oldham, R. K., & Dillman, R. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7438 · Cited by 204
Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2867 · Cited by 203
Corneal Antigen-Presenting Cells
Hamrah, P., & Dana, M. R. (2007) · Chemical Immunology and Allergy · doi:10.1159/000099254 · Cited by 187
Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., Slovak, M. L., Tallman, M. S., Willman, C. L., Erba, H., et al. (2009) · Blood · doi:10.1182/blood.v114.22.790.790 · Cited by 184
Methods for site-specific drug conjugation to antibodies
Behrens, C. R., & Liu, B. (2014) · mAbs · doi:10.4161/mabs.26632 · Cited by 171
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Blanc, V., Bousseau, A., Caron, A., Carrez, C., Lutz, R. J., & Lambert, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0485 · Cited by 170
Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review
Sassoon, I., & Blanc, V. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_1 · Cited by 157
On-target and Off-target-based Toxicologic Effects
Rudmann, D. G. (2012) · Toxicologic Pathology · doi:10.1177/0192623312464311 · Cited by 156
Tassone, P., Gozzini, A., Goldmacher, V. S., Shammas, M. A., Whiteman, K. R., Carrasco, D. R., Li, C., Allam, C. K., Venuta, S., Anderson, K. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0142 · Cited by 152
A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor GrowthIn vivo
Jackson, D., Gooya, J. M., Mao, S., Kinneer, K., XU, L. L., Camara, M., Fazenbaker, C. A., Fleming, R. L., Swamynathan, S., Meyer, D. L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1933 · Cited by 151
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
Pegram, M. D., & Slamon, D. (2000) · PubMed · Cited by 149
Drug‐conjugated antibodies for the treatment of cancer
Lambert, J. M. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12044 · Cited by 148
Hernández‐Caselles, T., Martinez‐Esparza, M., Pérez‐Oliva, A. B., Quintanilla-Cecconi, A. M., García-Alonso, A. M., Álvarez‐López, D. M. R., & García–Peñarrubia, P. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0205096 · Cited by 141
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Anatomy and Immunology of the Ocular Surface
Knop, E., & Knop, N. (2007) · KARGER eBooks · doi:10.1159/000099252 · Cited by 139
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M. E., Law, C., Senter, P. D., & Benjamin, D. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155549 · Cited by 136
Tannir, N. M., Forero, A., Ramchandren, R., Pal, S. K., Ansell, S. M., Infante, J. R., de Vos, S., Hamlin, P. A., Kim, S. K., Whiting, N. C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0151-0 · Cited by 128
Ocular toxicity and cancer chemotherapy: A review
Al‐Tweigeri, T., Nabholtz, J., & Mackey, J. R. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961001)78:7<1359::aid-cncr1>3.0.co;2-g · Cited by 125
Tassone, P., Goldmacher, V. S., Neri, P., Gozzini, A., Shammas, M. A., Whiteman, K. R., Hylander-Gans, L., Carrasco, D. R., Hideshima, T., Shringarpure, R., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0963 · Cited by 124
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Annunziata, C. M., Kohn, E. C., LoRusso, P. M., Houston, N. D., Coleman, R. L., Buzoianu, M., Robbie, G. J., & Lechleider, R. J. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9801-2 · Cited by 121
Oflazoglu, E., Stone, I. J., Gordon, K. A., Wood, C. G., Repasky, E. A., Grewal, I. S., Law, C., & Gerber, H. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0916 · Cited by 114
Lapusan, S., Vídriales, M., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., Dumontet, C., Morariu-Zamfir, R., Lambert, J. M., Ozoux, M., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9670-0 · Cited by 108
Ribrag, V., Dupuis, J., Tilly, H., Morschhauser, F., Lainé, F., Houot, R., Haïoun, C., Copie‐Bergman, C., Varga, A., Lambert, J. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0580 · Cited by 105
Beeram, M., Krop, I. E., Burris, H. A., Girish, S., Yu, W., Lu, M. W., Holden, S. N., & Modi, S. (2012) · Cancer · doi:10.1002/cncr.27622 · Cited by 103
Han, T. H., & Zhao, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058586 · Cited by 101
EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
Lee, J., Han, H. D., Shahzad, M. M. K., Kim, S. W., Mangala, L. S., Nick, A. M., Lü, C., Langley, R. R., Schmandt, R. E., Kim, H., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp231 · Cited by 90
Foerster, C. G., Cursiefen, C., & Kruse, F. E. (2008) · Cornea · doi:10.1097/ico.0b013e318166f483 · Cited by 80
Haddish‐Berhane, N., Shah, D. K., Ma, D., Leal, M., Gerber, H., Sapra, P., Barton, H. A., & Betts, A. M. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9329-x · Cited by 79
Mensen, A., Jöhrens, K., Anagnostopoulos, I., Demski, S., Oey, M., Stroux, A., Hemmati, P., Westermann, J., Blau, O., Wittenbecher, F., et al. (2014) · Blood · doi:10.1182/blood-2013-11-539031 · Cited by 75
Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 74
Investigational antibody-drug conjugates for hematological malignancies
Polson, A. G., Ho, W., & Ramakrishnan, V. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.539557 · Cited by 71
EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
Lee, J., Stone, R. L., Lee, S. J., Nam, E. J., Roh, J., Nick, A. M., Han, H., Shahzad, M. M. K., Kim, H., Mangala, L. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0017 · Cited by 71
Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Пили, Р., Kim, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0481 · Cited by 67
Antibody-maytansinoid conjugates for the treatment of myeloma
Lutz, R. J., & Whiteman, K. R. (2009) · mAbs · doi:10.4161/mabs.1.6.10029 · Cited by 62
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
Al-Katib, A. M., Aboukameel, A., Mohammad, R. M., Bissery, M.-C., & Zuany‐Amorim, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2808 · Cited by 58
CD33 Detection by Immunohistochemistry in Paraffin-Embedded Tissues
Hoyer, J. D., Grogg, K. L., Hanson, C. A., Gamez, J. D., & Doǧan, A. (2008) · American Journal of Clinical Pathology · doi:10.1309/e36008y2h08q1ayy · Cited by 54
Schrohl, A., Pedersen, H. C., Jensen, S. S., Nielsen, S. L., & Brünner, N. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04034.x · Cited by 49
Piccaluga, P. P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Visani, G., & Baccarani, M. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.01.009 · Cited by 45
Goff, L. K., Summers, K. E., Iqbal, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6258 · Cited by 39
Zigler, M., Shir, A., & Levitzki, A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.04.003 · Cited by 38
Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Dosio, F., Stella, B., Cerioni, S., Gastaldi, D., & Arpicco, S. (2013) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/15748928113089990045 · Cited by 38
Kheir, W. J., Sniegowski, M. C., El-Sawy, T., Li, A. L., & Esmaeli, B. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.02.004 · Cited by 36
Fourth World Antibody-Drug Conjugate Summit
Beck, A., Lambert, J. M., Sun, M. M. C., & Lin, K. (2012) · mAbs · doi:10.4161/mabs.21697 · Cited by 36
Jackson, D., & Stover, D. R. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1536-7 · Cited by 34
Trichomegaly of the eyelashes following treatment with cetuximab
Vaccaro, M., Pollicino, A., Barbuzza, O., & Guarneri, B. (2008) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2008.02842.x · Cited by 33
Gemtuzumab Ozogamicin: One Size Does Not Fit All—The Case for Personalized Therapy
Ravandi, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2693 · Cited by 31
Trichomegaly and other external eye side effects associated with epidermal growth factor
Fraunfelder, F. T., & Fraunfelder, F. W. (2011) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2011.636118 · Cited by 28
Mita, M. M., Ricart, A. D., Mita, A. C., Patnaik, A., Sarantopoulos, J., Sankhala, K. K., Fram, R. J., Qin, A., Watermill, J., & Tolcher, A. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3062 · Cited by 24
Ocular Toxicity Related to Cetuximab Monotherapy in Patients with Colorectal Cancer
Dranko, S., Kinney, C., & Ramanathan, R. K. (2006) · Clinical Colorectal Cancer · doi:10.3816/ccc.2006.n.040 · Cited by 22
Factors Involved in the Design of Cytotoxic Payloads for Antibody–Drug Conjugates
Widdison, W. C., & Chari, R. V. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5456-4_6 · Cited by 16
Moore, K. N., Ponte, J., LoRusso, P. M., Birrer, M. J., Bauer, T. M., Borghaei, H., O’Malley, D. M., Ruiz-Soto, R., Lutz, R., & Malik, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5571 · Cited by 16
Optimising the Delivery of Tubulin Targeting Agents through Antibody Conjugation
Stack, G. D., & Walsh, J. J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0810-9 · Cited by 12
Linker Technology and Impact of Linker Design on ADC Properties
Goldmacher, V. S., Singh, R., Chittenden, T. D., & Kovtun, Y. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5456-4_7 · Cited by 10
Moore, K. N., & Rowland, M. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.0998 · Cited by 8
Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine
Lambert, J. M., O’Leary, J. J., Whiteman, K. R., & Goldmacher, V. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5456-4_16 · Cited by 6
Xiao, Z., Jackson, D., & Tice, D. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5456-4_14 · Cited by 4
Targeted Therapy and Their Ocular Complications
Jusufbegovic, D., Triozzi, P. L., & Singh, A. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-40489-4_13 · Cited by 3
Rugo, H. S., Krop, I. E., & Chu, Y. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5456-4_11 · Cited by 2
Lambert, J. M., Blanc, V., Bail, N. L., & Bousseau, A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5456-4_9 · Cited by 1
Cited by
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Metadata
- Authors
- Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J.
- Venue
- Journal of Ocular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2015-12
- Volume
- 31
- Issue
- 10
- Pages
- 589-604
- ISSN
- 1080-7683 (ISSN-L)
- 1557-7732
- OpenAlex
- W2202939373
- Cited by
- 276
- References
- 81
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.